Literature DB >> 28237691

VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms.

Grażyna Gadomska1, Katarzyna Stankowska2, Joanna Boinska3, Robert Ślusarz3, Marzena Tylicka4, Małgorzata Michalska4, Anna Jachalska1, Danuta Rość4.   

Abstract

BACKGROUND AND
OBJECTIVE: Data from the literature indicate the relationship between the bone marrow microvessel density and the blood parameters of angiogenesis. The aim of this study was to evaluate selected parameters of angiogenesis (VEGF-A, sVEGFR-1, and sVEGFR-2) and their correlations with white blood cells, platelets, and red blood cells.
MATERIALS AND METHODS: The study included 72 patients (mean age, 61.84 years) with myeloproliferative neoplasms (MPNs): essential thrombocythemia (ET) (n=46), polycythemia vera (PV) (n=19), and primary myelofibrosis (PMF) (n=7). Serum VEGF-A, sVEGFR-1, and sVEGFR-2 were determined using the ELISA assay.
RESULTS: We observed a significantly higher level of VEGF-A and reduced concentrations of sVEGFR-1 and sVEGFR-2 in the whole group of patients with MPNs as compared to controls. Detailed analysis confirmed significantly higher level of VEGF-A and lower concentration of sVEGFR-2 in each subgroups of MPNs patients. However, sVEGFR-1 concentrations were significantly lower only in PV and ET patients.
CONCLUSIONS: The study showed an increased level of VEGF-A, which may indicate the intensity of neoangiogenesis in the bone marrow. Decreased sVEGFR-1 and sVEGFR-2 in the blood of patients with MPNs may reflect consumption of these soluble receptors.
Copyright © 2017 The Lithuanian University of Health Sciences. Production and hosting by Elsevier Sp. z o.o. All rights reserved.

Entities:  

Keywords:  BCR-ABL-negative myeloproliferative neoplasm; VEGF-A; sVEGFR-1; sVEGFR-2

Mesh:

Substances:

Year:  2017        PMID: 28237691     DOI: 10.1016/j.medici.2017.01.004

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  5 in total

1.  Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy.

Authors:  Lauren A Dalvin; Timothy W Olsen; Sophie J Bakri; Kristen McCullough; Ayalew Tefferi; Aref Al-Kali
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-21

2.  Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes.

Authors:  Laura Villani; Adriana Carolei; Vittorio Rosti; Margherita Massa; Rita Campanelli; Paolo Catarsi; Carlotta Abbà; Robert Peter Gale; Giovanni Barosi
Journal:  Genes (Basel)       Date:  2021-08-20       Impact factor: 4.096

3.  Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.

Authors:  Mónica Mejía-Ochoa; Paola Andrea Acevedo Toro; Jaiberth Antonio Cardona-Arias
Journal:  BMC Cancer       Date:  2019-06-17       Impact factor: 4.430

4.  VEGFA rs3025020 Polymorphism Contributes to CALR -Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis.

Authors:  Laura Villani; Vittorio Rosti; Margherita Massa; Rita Campanelli; Paolo Catarsi; Adriana Carolei; Carlotta Abbà; Annalisa de Silvstri; Robert Peter Gale; Giovanni Barosi
Journal:  TH Open       Date:  2021-11-09

5.  VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms.

Authors:  Tijana Subotički; Olivera Mitrović Ajtić; Emilija Živković; Miloš Diklić; Dragoslava Đikić; Milica Tošić; Bojana Beleslin-Čokić; Teodora Dragojević; Mirjana Gotić; Juan F Santibanez; Vladan Čokić
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.